- Ab00924-23.9 Anti-HER2 [C7b]
- Rabbit IgG-Fc fusion
- Ships in 5-6 weeks
Recombinant monoclonal antibody to HER2. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody C7b.
UniProt Accession Number of Target Protein: P04626
Alternative Name(s) of Target: NEU; HER-2; HER-2/neu; ERBB2; CD340; MLN 19; NGL; TKR1; erb-b2 receptor tyrosine kinase 2;
Immunogen: A llama was immunized with the HER2-expressing ovarian cancer cell line SKOv3 and a sdAb phage display library was built and used to perform biopannings. The first round of selection was performed on a purified recombinant HER2 ectodomain fused to a human Fc portion (HER2-Fc) followed by a second round on an HER2-positive SKBr3 cell line. After selection, 188 clones were screened and 92 clones were found to be positive by ELISA on HER2 positive cells. Twenty clones were analyzed by sequencing, and all of them corresponded to a unique clone named C7b.
Specificity: C7b specifically recognises HER2 at a different epitope to that recognised by Herceptin.
Application Notes: C7b has been used to enrich breast cancer cells (SKBr3) from a large excess of human peripheral blood mononuclear cells (Even-Desrumeaux 2012).
Antibody first published in:
Even-Desrumeaux et al. Single-domain antibodies: a versatile and rich source of binders for breast cancer diagnostic approaches Mol. BioSyst., 2012, 8, 2385–2394 PMID:22772166
Note on publication: Describes the generation of single-domain antibody fragments against cancer-specific antigens for the use in diagnostic tests for breast cancer, such as ELISA, IHC and microarray multiplex protein measurement by biomarker-based molecule diagnostic and prognostic cancer testing assays.